Pliant Therapeutics (PLRX) Expected to Announce Earnings on Monday

Pliant Therapeutics (NASDAQ:PLRX) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

Pliant Therapeutics (NASDAQ:PLRX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.17. On average, analysts expect Pliant Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Pliant Therapeutics Trading Up 4.3 %

Shares of Pliant Therapeutics stock opened at $1.69 on Friday. The stock has a market capitalization of $103.74 million, a P/E ratio of -0.51 and a beta of 1.46. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. Pliant Therapeutics has a 12-month low of $1.10 and a 12-month high of $16.52. The company has a 50-day simple moving average of $1.58 and a 200 day simple moving average of $8.31.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PLRX. Wells Fargo & Company lowered their price target on shares of Pliant Therapeutics from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, March 4th. Citigroup lowered their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Leerink Partners cut Pliant Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $33.00 to $2.00 in a report on Monday, March 3rd. Oppenheimer reiterated a “market perform” rating on shares of Pliant Therapeutics in a research note on Monday, February 10th. Finally, JPMorgan Chase & Co. downgraded shares of Pliant Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, February 10th. Twelve equities research analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.31.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.